1
|
Hassan M, Shahzadi S, Yasir M, Chun W, Kloczkowski A. Computational prognostic evaluation of Alzheimer's drugs from FDA-approved database through structural conformational dynamics and drug repositioning approaches. Sci Rep 2023; 13:18022. [PMID: 37865690 PMCID: PMC10590448 DOI: 10.1038/s41598-023-45347-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Accepted: 10/18/2023] [Indexed: 10/23/2023] Open
Abstract
Drug designing is high-priced and time taking process with low success rate. To overcome this obligation, computational drug repositioning technique is being promptly used to predict the possible therapeutic effects of FDA approved drugs against multiple diseases. In this computational study, protein modeling, shape-based screening, molecular docking, pharmacogenomics, and molecular dynamic simulation approaches have been utilized to retrieve the FDA approved drugs against AD. The predicted MADD protein structure was designed by homology modeling and characterized through different computational resources. Donepezil and galantamine were implanted as standard drugs and drugs were screened out based on structural similarities. Furthermore, these drugs were evaluated and based on binding energy (Kcal/mol) profiles against MADD through PyRx tool. Moreover, pharmacogenomics analysis showed good possible associations with AD mediated genes and confirmed through detail literature survey. The best 6 drug (darifenacin, astemizole, tubocurarine, elacridar, sertindole and tariquidar) further docked and analyzed their interaction behavior through hydrogen binding. Finally, MD simulation study were carried out on these drugs and evaluated their stability behavior by generating root mean square deviation and fluctuations (RMSD/F), radius of gyration (Rg) and soluble accessible surface area (SASA) graphs. Taken together, darifenacin, astemizole, tubocurarine, elacridar, sertindole and tariquidar displayed good lead like profile as compared with standard and can be used as possible therapeutic agent in the treatment of AD after in-vitro and in-vivo assessment.
Collapse
Affiliation(s)
- Mubashir Hassan
- The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, 43205, USA.
| | - Saba Shahzadi
- The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, 43205, USA
| | - Muhammad Yasir
- Department of Pharmacology, College of Medicine, Kangwon National University, Chuncheon, South Korea
| | - Wanjoo Chun
- Department of Pharmacology, College of Medicine, Kangwon National University, Chuncheon, South Korea
| | - Andrzej Kloczkowski
- The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, 43205, USA.
- Department of Pediatrics, The Ohio State University, Columbus, OH, 43205, USA.
| |
Collapse
|
2
|
Alakbaree M, Amran S, Shamsir M, Ahmed HH, Hamza M, Alonazi M, Warsy A, Latif NA. Human G6PD variant structural studies: Elucidating the molecular basis of human G6PD deficiency. GENE REPORTS 2022. [DOI: 10.1016/j.genrep.2022.101634] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Devendra R, Gupta V, Shanmugam R, Singh MPSS, Patel P, Valecha N, Mishra N, Ahmed N, Hoti SL, Hegde HV, Warang P, Chiddarwar A, Kedar P, Mayekar P, Mukherjee MB. Prevalence and spectrum of mutations causing G6PD deficiency in Indian populations. INFECTION GENETICS AND EVOLUTION 2020; 86:104597. [PMID: 33069889 DOI: 10.1016/j.meegid.2020.104597] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2020] [Revised: 10/12/2020] [Accepted: 10/13/2020] [Indexed: 12/21/2022]
Abstract
BACKGROUND Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common human erythroenzymopathy affecting around 10% of the world population. India is endemic for malaria and antimalarial drugs are known to induce haemolysis in G6PD deficient individuals. Here we report the prevalence as well as the molecular diversity of G6PD deficiency in geographical regions of India. METHODS AND RESULTS A total of 20,896 individuals (11,838 males and 9058 females) were screened by DPIP dye decolorisation method followed by quantitation of G6PD enzyme activity on the suspected samples. Molecular analysis was undertaken in a total of 350 G6PD deficient individuals by PCR-RFLP and DNA sequencing. A structural characteristic of the novel variant was deduced by using DynaMut web-server. The prevalence rate of G6PD deficiency varied between 0.8 and 6.3% with an overall prevalence of 1.9%. A total of twelve mutations were identified. Of the total deleterious alleles detected G6PD Orissa (56.5%) was found to be the most predominant variant followed by G6PD Mediterranean (23.6%). G6PD Mediterranean, G6PD Kaiping and G6PD Mahidol were found to be severely deficient variant and 14.1% of them showed undetectable activity. A novel mutation c.544C➔G (R182G) in exon 6 was identified in one tribal male where substitution of arginine by glycine, likely causes the alteration in the alpha helix leading to disruption of secondary structure of the protein. CONCLUSION There are large differences in the distribution of G6PD causal variants between Indian states, and this may have implications for the treatment in the malaria endemic areas.
Collapse
Affiliation(s)
- Rati Devendra
- ICMR-National Institute of Immunohaematology (NIIH), 13th Floor, K.E.M Hospital campus, Parel, Mumbai 400012. India
| | - Vinodkumar Gupta
- ICMR-National Institute of Immunohaematology (NIIH), 13th Floor, K.E.M Hospital campus, Parel, Mumbai 400012. India
| | - Rajasubramaniam Shanmugam
- ICMR-National Institute for Research in Tribal Health (NIRTH), Department of Health Research, Ministry of Health & Family Welfare, NIRTH Complex, Nagpur Road, P.O.- Garha, Jabalpur, Madhya Pradesh 482003, India
| | - M P S S Singh
- ICMR-National Institute for Research in Tribal Health (NIRTH), Department of Health Research, Ministry of Health & Family Welfare, NIRTH Complex, Nagpur Road, P.O.- Garha, Jabalpur, Madhya Pradesh 482003, India
| | - Purushottam Patel
- ICMR-National Institute for Research in Tribal Health (NIRTH), Department of Health Research, Ministry of Health & Family Welfare, NIRTH Complex, Nagpur Road, P.O.- Garha, Jabalpur, Madhya Pradesh 482003, India
| | - Neena Valecha
- ICMR-National Institute of Malaria Research (NIMR), Sector 8 Dwarka, Dwarka, New Delhi, Delhi 110077, India
| | - Neelima Mishra
- ICMR-National Institute of Malaria Research (NIMR), Sector 8 Dwarka, Dwarka, New Delhi, Delhi 110077, India
| | - Naseem Ahmed
- ICMR-National Institute of Malaria Research (NIMR), Sector 8 Dwarka, Dwarka, New Delhi, Delhi 110077, India
| | - S L Hoti
- ICMR-National Institute of Traditional Medicine (NITM), Nehru Nagar, Belgavi, Karnataka 590010, India
| | - Harsha V Hegde
- ICMR-National Institute of Traditional Medicine (NITM), Nehru Nagar, Belgavi, Karnataka 590010, India
| | - Prashant Warang
- ICMR-National Institute of Immunohaematology (NIIH), 13th Floor, K.E.M Hospital campus, Parel, Mumbai 400012. India
| | - Ashish Chiddarwar
- ICMR-National Institute of Immunohaematology (NIIH), 13th Floor, K.E.M Hospital campus, Parel, Mumbai 400012. India
| | - Prabhakar Kedar
- ICMR-National Institute of Immunohaematology (NIIH), 13th Floor, K.E.M Hospital campus, Parel, Mumbai 400012. India
| | - Pramod Mayekar
- ICMR-National Institute of Immunohaematology (NIIH), 13th Floor, K.E.M Hospital campus, Parel, Mumbai 400012. India
| | - Malay B Mukherjee
- ICMR-National Institute of Immunohaematology (NIIH), 13th Floor, K.E.M Hospital campus, Parel, Mumbai 400012. India.
| |
Collapse
|